LST Transforms With Acquisitions, Eyes Growth

Light Science Technologies (LST) has announced its unaudited interim results for the six months ending May 31, 2026, a period described as transformational. The company successfully raised £6.6 million, which funded three strategic acquisitions, including RLUK Injection Ltd and its patented Injectaclad system. These acquisitions are fundamentally reshaping LST's operational structure and are expected to drive high-margin growth.

During the first half of the financial year, LST reported revenue of £3.73 million with a gross margin of 30.5%. The adjusted operating loss was £0.69 million, attributed to integration costs and delays in Passive Fire Protection (PFP) project approvals. The PFP division has integrated Injectaclad and established a northern distribution hub in Manchester, securing significant commercial activity.

The Contract Electronics Manufacturing division has onboarded four new clients, projected to contribute up to £1 million annually. Concurrently, the AgTech division is advancing a £0.6 million project with Nottingham Trent University and has secured an additional £0.3 million university contract in Wales.

Trading momentum has significantly improved since the interim period, with £2.15 million in revenue generated in the two months to July 31, 2026. The company maintains a committed forward order book of £3.09 million. Management is confident in a substantially stronger second half and a return to profitable growth, supported by accelerating PFP pipeline conversion due to improved Building Safety Regulator approvals.